Latest / Raleigh News Today | 2 Min News | The Daily News Now!
Ionis Takes Double Blow in Biotech | Raleigh News
Ionis Pharmaceuticals took a brutal hit after its heart drug Wainua failed in a major trial, wiping out nearly a quarter of its value in one day. The blow intensified the next day when Roche canceled two Huntington’s programs, including tominersen, citing unmet goals and safety concerns. Analysts slashed price targets but mostly kept “Buy” ratings, seeing the setbacks as temporary. Competitors like Alnylam and BridgeBio gained as the ATTR-CM market opened up. Still, Ionis isn’t out of the game — Wainua is already approved and profitable in 20+ countries for another nerve condition, and the…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.